Quidel Co. (NASDAQ:QDEL) CEO Douglas C. Bryant sold 7,217 shares of the company’s stock in a transaction that occurred on Wednesday, October 31st. The stock was sold at an average price of $65.10, for a total value of $469,826.70. Following the sale, the chief executive officer now directly owns 301,530 shares of the company’s stock, valued at approximately $19,629,603. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
QDEL opened at $66.68 on Monday. Quidel Co. has a 1-year low of $33.01 and a 1-year high of $77.63. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.10 and a quick ratio of 0.71. The company has a market capitalization of $2.60 billion, a PE ratio of -952.57, a price-to-earnings-growth ratio of 1.04 and a beta of 1.05.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Tuesday, August 7th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.12. Quidel had a return on equity of 19.39% and a net margin of 4.63%. The company had revenue of $103.16 million during the quarter, compared to analysts’ expectations of $102.15 million. As a group, sell-side analysts predict that Quidel Co. will post 2.55 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of QDEL. Guggenheim Capital LLC bought a new stake in shares of Quidel in the first quarter valued at approximately $1,262,000. Xact Kapitalforvaltning AB acquired a new position in shares of Quidel in the first quarter valued at $241,000. WINTON GROUP Ltd acquired a new position in shares of Quidel in the first quarter valued at $575,000. Winslow Evans & Crocker Inc. acquired a new position in shares of Quidel in the second quarter valued at $236,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Quidel in the second quarter valued at $2,300,000. 88.36% of the stock is owned by institutional investors.
Quidel Company Profile
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Featured Article: Do You Need a Fiduciary?
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.